Rozlytrek

Chemical Nameentrectinib
Dosage FormCapsule (oral; 100 mg, 200 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyGenentech Inc.
Approval Year2019

Indication

  • Rozlytrek is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
  • Rozlytrek is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.
Last updated on 11/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rozlytrek (entrectinib) Prescribing Information 2019Genentech